Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Receivables: 2011-2024

Historic Change in Receivables for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $1.3 million.

  • Niagen Bioscience's Change in Receivables fell 63.66% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 172.98%. This contributed to the annual value of $1.3 million for FY2024, which is 156.72% up from last year.
  • Niagen Bioscience's Change in Receivables amounted to $1.3 million in FY2024, which was up 156.72% from -$2.3 million recorded in FY2023.
  • Niagen Bioscience's Change in Receivables' 5-year high stood at $3.3 million during FY2022, with a 5-year trough of -$2.3 million in FY2023.
  • Moreover, its 3-year median value for Change in Receivables was $1.3 million (2024), whereas its average is $781,000.
  • In the last 5 years, Niagen Bioscience's Change in Receivables surged by 1,361.36% in 2020 and then tumbled by 167.94% in 2023.
  • Yearly analysis of 5 years shows Niagen Bioscience's Change in Receivables stood at $555,000 in 2020, then surged by 364.50% to $2.6 million in 2021, then increased by 28.74% to $3.3 million in 2022, then crashed by 167.94% to -$2.3 million in 2023, then skyrocketed by 156.72% to $1.3 million in 2024.